TGTX vs. MOR, RNA, FOLD, ARWR, MRVI, CORT, MRUS, BHC, MLTX, and XENE
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include MorphoSys (MOR), Avidity Biosciences (RNA), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Maravai LifeSciences (MRVI), Corcept Therapeutics (CORT), Merus (MRUS), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
In the previous week, MorphoSys had 8 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for MorphoSys and 1 mentions for TG Therapeutics. MorphoSys' average media sentiment score of 0.63 beat TG Therapeutics' score of 0.30 indicating that MorphoSys is being referred to more favorably in the news media.
TG Therapeutics has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 14.24% compared to MorphoSys' net margin of -226.79%. TG Therapeutics' return on equity of 31.34% beat MorphoSys' return on equity.
TG Therapeutics presently has a consensus target price of $29.83, indicating a potential upside of 81.03%. MorphoSys has a consensus target price of $11.78, indicating a potential downside of 38.00%. Given TG Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe TG Therapeutics is more favorable than MorphoSys.
TG Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
TG Therapeutics received 626 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 9.2% of TG Therapeutics shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
TG Therapeutics beats MorphoSys on 15 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
